Search Results - richard+siegel

5 Results

Sort By:

Human TL 1A-transgenic Mouse as a Disease and Therapeutic Model

This technology includes mouse models of TL 1A diseases, such as inflammatory bowel disease and rheumatoid arthritis, to be used as a platform for studying therapeutic agents. The TNF family cytokine TL 1A co-stimulates T-cells through Its receptor and is required for autoimmune pathology driven by diverse T-cell subsets. Blocking TL 1A in mouse models...

Published: 7/30/2024 | Inventor(s): Richard Siegel, Francoise Meylan

Keywords(s):

Category(s): Application > Research Materials, Collaboration Sought > Materials Available, ResearchProducts > Animal Models

Monoclonal Anti-mouse and Anti-human TL 1A Antibodies for Diagnostic and Therapeutic Utilization

This technology includes antibodies against TL 1A for the inhibition of TL 1A-DR3 interactions for the diagnosis and treatment of various autoimmune diseases. Through the use of our developed hamster anti-mouse and mouse anti-human monoclonal antibodies, we’ve demonstrated that treatment with anti-mouse TL 1A prevented collagen-induced arthritis...

Published: 7/30/2024 | Inventor(s): Richard Siegel, Francoise Meylan, Yun-Jeong Song

Keywords(s):

Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Licensing, ResearchProducts > Antibodies, TherapeuticArea > Immunology

TL1A Transgenic Mice for the Study of Inflammatory Bowel Disease (IBD) and Allergic-Type Immune Responses

TL1A is a TNF family cytokine that co-stimulates T-cell proliferation and cytokine production through its interactions with the TNF family receptor DR3. TL1A-DR3 interactions have been shown to be important for the development of autoimmune inflammatory diseases, including inflammatory bowel disease (IBD). In order to probe the role of TL1A-DR3 interactions...

Published: 10/28/2024 | Inventor(s): Francoise Meylan, Richard Siegel

Keywords(s): Allergic-type, Autoimmune, BOWEL, DR3, IBD, IDXXXX, IL-13, IMMUNE, INFLAMMATORY, inflammatory bowel disease, IXXXXX, Mouse, Murine, TL1A, TL1A/DR3, TLlA-transgenic, tnf, TNFSF15

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Application > Research Materials, Application > Diagnostics

Antibodies Against TL1A, a TNF-Family Cytokine, for the Treatment and Diagnosis of Autoimmune Inflammatory Diseases

Autoimmune inflammatory diseases occur in greater than five percent of the United States population; this disease group includes asthma, multiple sclerosis, rheumatoid arthritis, and lupus. Treatments generally include immunosuppressants or anti-inflammatory drugs, which can have serious side effects; recently, more specific immunomodulatory therapies...

Published: 7/30/2024 | Inventor(s): Francoise Meylan, Yun-Jeong Song, Richard Siegel

Keywords(s): antibodies, ANTIBODY, ANTI-HUMAN, Anti-mouse, Autoimmune, diagnostic, DR3, IA3XXX, IAXXXX, IB3XXX, IBXXXX, Immunomodulation, immuno-modulator, immunomodulatory, INFLAMMATORY, inflammatory disease, IXXXXX, monoclonal, Monoclonal Antibodies, Monoclonal Antibody, Patent Category - Biotechnology, therapeutic, TL1A, tnf, TNFRSF25, TNFSF15, tumor necrosis factor, USES

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Immunology

Amelioration of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptors

The invention relates to compositions of matter and methods for treating arthritis by modulating Tumor Necrosis Factor Alpha (TNF-alpha) signaling. TNF-alpha plays a key role in the pathogenesis of numerous diseases including rheumatoid and septic arthritis, and other autoimmune and inflammatory diseases. TNF-alpha mediates its effects through receptors...

Published: 10/28/2024 | Inventor(s): Michael Lenardo, Francis Chan, Richard Siegel

Keywords(s): ASSEMBLY, BCXXXX, CB3AXX, CBXXXX, CC1XXX, CCXXXX, CXXXXX, Domain, factor, FAMILY, FUNCTION., Identification, Listed LPM Hastings as of 4/15/2015, Mediates, NECROSIS, Novel, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, PRE-LIGAND, RECEPTOR, SACGHS DNA Patent Initial Set, That, tumor

Category(s): Collaboration Sought > Licensing, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Oncology